Table 1 Expression of IL-17 by mast cells, T cells and macrophages in synovial tissue
Demographics | ACPA+ RA (n= 34) | ACPA- RA (n= 25) | OA (n= 29) | Pvalue |
|---|---|---|---|---|
Age (years) | 55 (32 to 80) | 63 (19 to 80) | 67 (42 to 83) | |
Gender (females/males) | 22/12 | 14/11 | 21/8 | |
Disease duration (years) | 7 (0 to 28) | 8 (0 to 24) | Unknown | |
Median IL-17+ cells | 21 (0 to 118) | 12 (1 to 61) | 17 (0 to 50) | 0.381 |
IL-17+ mast cells (%) | 97 (40 to 100) | 96 (0 to 100) | 93 (0 to 100) | 0.969 |
IL-17+ T cells (%) | 0 (0 to 100) | 0 (0 to 24) | 2 (0 to 49) | 0.558 |
IL-17+ MØ (%) | 0 (0 to 78) | 4 (0 to 100) | 1 (0 to 58) | 0.382 |
Median MCs | 28 (0 to 123) | 19 (0 to 92) | 25 (0 to 76) | 0.198 |
MCs (CD117+) expressing IL-17 (%) | 91 (13 to 100) | 83 (0 to 100) | 96 (4 to 100) | 0.599 |
T cells (CD3+), n | 21 (0 to 592) | 10 (0 to 115) | 11 (0 to 265) | 0.609 |
T cells (CD3+) expressing IL-17 (%) | 0 (0 to 60) | 0 (0 to 66) | 1 (0 to 78) | 0.149 |
MØ (CD68+), n | 71 (1 to 390) | 53 (1 to 302) | 66 (2 to 231) | 0.634 |
MØ (CD68+) expressing IL-17 (%) | 0 (0 to 16) | 0 (0 to 14) | 0 (0 to 11) | 0.689 |